Bank of New York Mellon Corp Cuts Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Bank of New York Mellon Corp lessened its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 22.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 193,315 shares of the company’s stock after selling 56,213 shares during the period. Bank of New York Mellon Corp’s holdings in Voyager Therapeutics were worth $1,096,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of VYGR. Empowered Funds LLC raised its stake in Voyager Therapeutics by 5.4% in the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after buying an additional 2,278 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Voyager Therapeutics in the 3rd quarter valued at $74,000. Massachusetts Financial Services Co. MA raised its position in shares of Voyager Therapeutics by 19.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 171,856 shares of the company’s stock worth $1,005,000 after acquiring an additional 28,333 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Voyager Therapeutics by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock worth $804,000 after purchasing an additional 3,473 shares during the last quarter. Finally, FMR LLC boosted its position in Voyager Therapeutics by 26.9% during the third quarter. FMR LLC now owns 92,498 shares of the company’s stock valued at $541,000 after purchasing an additional 19,622 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Trading Up 0.8 %

NASDAQ:VYGR opened at $3.91 on Tuesday. The firm has a fifty day simple moving average of $4.62 and a 200-day simple moving average of $5.71. Voyager Therapeutics, Inc. has a 12 month low of $3.56 and a 12 month high of $10.66. The company has a market capitalization of $215.86 million, a P/E ratio of 5.51 and a beta of 0.99.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.24). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $4.39 million for the quarter, compared to analysts’ expectations of $16.58 million. During the same quarter in the previous year, the firm posted $1.25 EPS. Equities analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have commented on VYGR. Cantor Fitzgerald reiterated an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, March 13th. Citigroup began coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price for the company. Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $14.86.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.